Presumably we'll see the Quarterly this week. All the numbers are important but for me it's all about the growth in Adapt sales (none of us are s/holders for infusion, and vax as a money earner is no time soon).
The US sales team has been stripped down and rebuilt and the European team has been restructured. Vascucel has been properly launched. The effects of this should now be appearing in this week's Adapt sales figure - I'm hoping for $2.4m.
On a subtler level, it will also be fundamentally important to see the growth from the previous corresponding period (PCP) last year. ($1.5m). This growth figure use to track around 60% but has now fallen (with the restructure of the sales teams) to 10%. This should bounce back now to say 60% - and in Q1FY18, perhaps 100%.
It's all about Adapt.
Adapt sales - $2.4m
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.43 |
Change
-0.120(1.04%) |
Mkt cap ! $241.6M | |||
| Open | High | Low | Value | Volume |
| $11.58 | $11.58 | $11.17 | $196.0K | 17.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30 | $11.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 200 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |